Novo Nordisk A/S (NVO)
NVO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from DKK at 6.6774 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | NVO on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | Not reported by the screener |
| SEC CIK | 0000353278 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $46.3B |
| Net income | $15.3B |
| Operating income | Not in SEC XBRL data |
| Net margin | 33.1% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 11.0× |
| P/S (computed) | 3.6× |
Reported in DKK; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 20-F | 2026-02-04 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -10.4% |
| 3 months | -26.0% |
| Year to date | -25.1% |
| 1 year | -33.7% |
| From 52-week high | -40.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
| AZN | AstraZeneca PLC | $155.82 | -1.58% | $241.6B |
| BMY | Bristol-Myers Squibb Company | $56.67 | -1.58% | $115.8B |
| NVS | Novartis AG | $142.41 | -0.99% | $271.7B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier